Do analysts recommend CALT or FENC?

Adherex Technologies has a consensus price target of $15.40, indicating a potential upside of 71.11%. Given Adherex Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Adherex Technologies is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Adherex Technologies 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Does the media prefer MPLT or FENC?

In the previous week, Adherex Technologies had 1 more articles in the media than Maplight Therapeutics. MarketBeat recorded 3 mentions for Adherex Technologies and 2 mentions for Maplight Therapeutics. Adherex Technologies' average media sentiment score of 0.94 beat Maplight Therapeutics' score of 0.93 indicating that Adherex Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adherex Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XERS or FENC?

In the previous week, Xeris Biopharma had 4 more articles in the media than Adherex Technologies. MarketBeat recorded 7 mentions for Xeris Biopharma and 3 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.94 beat Xeris Biopharma's score of 0.26 indicating that Adherex Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Adherex Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer COLL or FENC?

In the previous week, Adherex Technologies had 1 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 3 mentions for Adherex Technologies and 2 mentions for Collegium Pharmaceutical. Adherex Technologies' average media sentiment score of 0.94 beat Collegium Pharmaceutical's score of 0.93 indicating that Adherex Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adherex Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Adherex Technologies (FENC) Competitors

$9.00 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$8.98 -0.02 (-0.17%)

As of 06/12/2026 04:10 PM Eastern

Compare

FENC vs. CALT, IMTX, MPLT, XERS, and COLL

Should you buy Adherex Technologies stock or one of its competitors? MarketBeat compares Adherex Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adherex Technologies include Calliditas Therapeutics AB (publ) (CALT), Immatics (IMTX), Maplight Therapeutics (MPLT), Xeris Biopharma (XERS), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry.

How does Adherex Technologies compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Adherex Technologies has a consensus price target of $15.40, indicating a potential upside of 71.11%. Given Adherex Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Adherex Technologies is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Adherex Technologies had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Adherex Technologies and 0 mentions for Calliditas Therapeutics AB (publ). Adherex Technologies' average media sentiment score of 0.94 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Adherex Technologies	Positive

Adherex Technologies has a net margin of -17.12% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Adherex Technologies' return on equity of -43.87% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Adherex Technologies	-17.12%	-43.87%	-11.35%

Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Adherex Technologies has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Adherex Technologies is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Adherex Technologies	$44.64M	7.03	-$9.74M	-$0.29	N/A

Summary

Adherex Technologies beats Calliditas Therapeutics AB (publ) on 14 of the 17 factors compared between the two stocks.

How does Adherex Technologies compare to Immatics?

Adherex Technologies (NASDAQ:FENC) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Adherex Technologies had 2 more articles in the media than Immatics. MarketBeat recorded 3 mentions for Adherex Technologies and 1 mentions for Immatics. Adherex Technologies' average media sentiment score of 0.94 beat Immatics' score of 0.93 indicating that Adherex Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Adherex Technologies	Positive
Immatics	Positive

Adherex Technologies has a net margin of -17.12% compared to Immatics' net margin of -572.35%. Adherex Technologies' return on equity of -43.87% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-17.12%	-43.87%	-11.35%
Immatics	-572.35%	-47.36%	-39.35%

Adherex Technologies has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, Immatics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

Adherex Technologies currently has a consensus target price of $15.40, suggesting a potential upside of 71.11%. Immatics has a consensus target price of $20.80, suggesting a potential upside of 121.75%. Given Immatics' higher possible upside, analysts plainly believe Immatics is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Adherex Technologies has higher earnings, but lower revenue than Immatics. Adherex Technologies is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	7.03	-$9.74M	-$0.29	N/A
Immatics	$54.60M	23.03	-$222.26M	-$1.99	N/A

Summary

Adherex Technologies beats Immatics on 10 of the 17 factors compared between the two stocks.

How does Adherex Technologies compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Adherex Technologies (NASDAQ:FENC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Adherex Technologies had 1 more articles in the media than Maplight Therapeutics. MarketBeat recorded 3 mentions for Adherex Technologies and 2 mentions for Maplight Therapeutics. Adherex Technologies' average media sentiment score of 0.94 beat Maplight Therapeutics' score of 0.93 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adherex Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

55.5% of Adherex Technologies shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by company insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Maplight Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Maplight Therapeutics' return on equity of 0.00% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Adherex Technologies	-17.12%	-43.87%	-11.35%

Adherex Technologies has higher revenue and earnings than Maplight Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Adherex Technologies	$44.64M	7.03	-$9.74M	-$0.29	N/A

Maplight Therapeutics currently has a consensus price target of $37.78, suggesting a potential upside of 36.14%. Adherex Technologies has a consensus price target of $15.40, suggesting a potential upside of 71.11%. Given Adherex Technologies' higher probable upside, analysts clearly believe Adherex Technologies is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.00
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Adherex Technologies beats Maplight Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Adherex Technologies compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Xeris Biopharma presently has a consensus target price of $10.80, indicating a potential upside of 59.06%. Adherex Technologies has a consensus target price of $15.40, indicating a potential upside of 71.11%. Given Adherex Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Adherex Technologies is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Xeris Biopharma had 4 more articles in the media than Adherex Technologies. MarketBeat recorded 7 mentions for Xeris Biopharma and 3 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.94 beat Xeris Biopharma's score of 0.26 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adherex Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has a net margin of 3.81% compared to Adherex Technologies' net margin of -17.12%. Xeris Biopharma's return on equity of 735.00% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Adherex Technologies	-17.12%	-43.87%	-11.35%

Xeris Biopharma has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Xeris Biopharma has higher revenue and earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	4.02	$550K	$0.06	113.17
Adherex Technologies	$44.64M	7.03	-$9.74M	-$0.29	N/A

Summary

Xeris Biopharma and Adherex Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Adherex Technologies compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

55.5% of Adherex Technologies shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Collegium Pharmaceutical has a net margin of 9.41% compared to Adherex Technologies' net margin of -17.12%. Collegium Pharmaceutical's return on equity of 95.18% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Adherex Technologies	-17.12%	-43.87%	-11.35%

Collegium Pharmaceutical has higher revenue and earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.44	$62.87M	$2.04	16.98
Adherex Technologies	$44.64M	7.03	-$9.74M	-$0.29	N/A

Collegium Pharmaceutical has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Collegium Pharmaceutical presently has a consensus target price of $57.50, indicating a potential upside of 65.99%. Adherex Technologies has a consensus target price of $15.40, indicating a potential upside of 71.11%. Given Adherex Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Adherex Technologies is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Adherex Technologies had 1 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 3 mentions for Adherex Technologies and 2 mentions for Collegium Pharmaceutical. Adherex Technologies' average media sentiment score of 0.94 beat Collegium Pharmaceutical's score of 0.93 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adherex Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Adherex Technologies beats Collegium Pharmaceutical on 9 of the 16 factors compared between the two stocks.

Get Adherex Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FENC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FENC vs. The Competition

Export

Metric	Adherex Technologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$314.01M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-31.03	20.00	24.00	24.42
Price / Sales	7.03	306.82	514.36	111.24
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	8.65	8.32	10.54	6.82
Net Income	-$9.74M	$23.94M	$3.57B	$337.56M
7 Day Performance	1.12%	1.84%	0.60%	1.17%
1 Month Performance	-7.69%	-0.04%	1.56%	3.16%
1 Year Performance	13.49%	44.82%	25.42%	30.58%

Adherex Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FENC Adherex Technologies	4.4607 of 5 stars	$9.00 flat	$15.40 +71.1%	+13.5%	$314.01M	$44.64M	N/A	10	News Coverage
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
IMTX Immatics	2.8198 of 5 stars	$9.06 +2.1%	$20.80 +129.6%	+53.3%	$1.19B	$54.60M	N/A	260
MPLT Maplight Therapeutics	3.5019 of 5 stars	$30.35 +9.2%	$37.78 +24.5%	N/A	$1.18B	N/A	N/A	109
XERS Xeris Biopharma	3.0064 of 5 stars	$6.93 +3.3%	$10.80 +55.8%	+56.1%	$1.16B	$291.85M	115.50	290	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FENC) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adherex Technologies (FENC) Competitors

FENC vs. CALT, IMTX, MPLT, XERS, and COLL

How does Adherex Technologies compare to Calliditas Therapeutics AB (publ)?

Summary

How does Adherex Technologies compare to Immatics?

Summary

How does Adherex Technologies compare to Maplight Therapeutics?

Summary

How does Adherex Technologies compare to Xeris Biopharma?

Summary

How does Adherex Technologies compare to Collegium Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FENC vs. The Competition

Adherex Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adherex Technologies (FENC) Competitors

FENC vs. CALT, IMTX, MPLT, XERS, and COLL

How does Adherex Technologies compare to Calliditas Therapeutics AB (publ)?

Do institutionals and insiders believe in CALT or FENC?

Do analysts recommend CALT or FENC?

Does the media prefer CALT or FENC?

Is CALT or FENC more profitable?

Which has more volatility & risk, CALT or FENC?

Which has stronger valuation and earnings, CALT or FENC?

Summary

How does Adherex Technologies compare to Immatics?

Does the media refer more to FENC or IMTX?

Is FENC or IMTX more profitable?

Which has more risk and volatility, FENC or IMTX?

Do analysts recommend FENC or IMTX?

Do insiders and institutionals have more ownership in FENC or IMTX?

Which has preferable valuation & earnings, FENC or IMTX?

Summary

How does Adherex Technologies compare to Maplight Therapeutics?

Does the media prefer MPLT or FENC?

Do institutionals & insiders hold more shares of MPLT or FENC?

Is MPLT or FENC more profitable?

Which has better earnings & valuation, MPLT or FENC?

Do analysts rate MPLT or FENC?

Summary

How does Adherex Technologies compare to Xeris Biopharma?

Do analysts recommend XERS or FENC?

Do institutionals and insiders have more ownership in XERS or FENC?

Does the media favor XERS or FENC?

Is XERS or FENC more profitable?

Which has more volatility & risk, XERS or FENC?

Which has preferable earnings and valuation, XERS or FENC?

Summary

How does Adherex Technologies compare to Collegium Pharmaceutical?

Do insiders and institutionals believe in COLL or FENC?

Is COLL or FENC more profitable?

Which has higher valuation & earnings, COLL or FENC?

Which has more risk and volatility, COLL or FENC?

Do analysts recommend COLL or FENC?

Does the media prefer COLL or FENC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FENC vs. The Competition

Adherex Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools